Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,409 across all filing types
Latest filing 2026-03-02 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and contains tables detailing share repurchase activities by Sanofi. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2026-03-02 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and provides a detailed table of transactions involving the company's own shares over a specific period (23 February 2020 to 27 February 2020). This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of a company buying back or selling its own shares.
2026-03-02 English
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing that their drug 'rilzabrutinib' has received orphan drug designation in Japan for IgG4-related disease. It provides details on the drug's clinical trial status, regulatory context, and background information on the disease and the company. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it is the primary source of the news itself. As a general corporate announcement regarding regulatory progress, it falls under the 'Regulatory Filings' (RNS) category.
2026-03-02 French
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi announcing that their drug, rilzabrutinib, has been granted orphan drug designation in Japan for IgG4-related disease. It provides details on the clinical study, the nature of the disease, and the regulatory status of the drug. As this is a general corporate announcement regarding regulatory milestones and product development that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS).
2026-03-02 English
Communiqué de presse : Dupixent de Sanofi et Regeneron recommandé pour approbation dans l'UE dans le traitement de l'urticaire chronique spontanée chez les jeunes enfants dont les symptômes persistent
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the drug Dupixent. It details clinical trial results, regulatory status, and forward-looking statements. As it is a general regulatory announcement regarding product development and regulatory milestones that does not fit into specific categories like financial reports or shareholder voting, it is classified as a Regulatory Filing (RNS).
2026-02-27 French
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the approval of the drug Dupixent. This is a standard corporate announcement regarding regulatory progress for a product candidate. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement, it falls under the general regulatory and corporate announcement category.
2026-02-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.